A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma

Trial Profile

A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 May 2018

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Feb 2018 Phase has been changed to 3 to 2.
    • 20 Jan 2018 Results from the safety run in phase (n= 11) presented at the 2018 Gastrointestinal Cancers Symposium
    • 06 Jun 2017 According to trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology, eleven patients have been enrolled as of February 1 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top